FDA Approves VOYXACT to Treat Kidney Disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. 

Efgartigimod Treatment Increases Spending for CIDP Patients

A new study has found that introducing efgartigimod alfa as a treatment option in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who are currently receiving subcutaneous immune globulin (IG) or intravenous IG would result in substantially increased spending in the treatment of CIPD.

RSV Poses Significant Threat to Patients with Systemic Autoimmune Rheumatic Diseases

A retrospective cohort study has found respiratory syncytial virus infections are associated with substantial morbidity among patients with systemic autoimmune rheumatic diseases, with more than half of infected individuals requiring hospitalization. 

FDA Approves Libtayo for Cutaneous Squamous Call Carcinoma

The U.S. Food and Drug Administration has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

Study Finds Possible Link Between Chronic Pain and Eosinophilia

A small study of medical records unexpectedly found that 12 percent of chronic pain patients who were treated with spinal cord stimulation or an implanted pain medicine pump had a white blood cell condition called eosinophilia.

Study Shows ALS May Be an Autoimmune Disorder

Researchers at La Jolla Institute for Immunology and Columbia University Irving Medical Center have discovered that amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, may be an autoimmune disorder.

Update on Premenstrual Dysphoric Disorder (PMDD)

This severe form of PMS is characterized by significant mood and physical symptoms, and is now recognized and listed as a mental disorder that can be treated and even cured.

FDA Fast Tracks Immunotherapy for HER2-Positive Breast Cancer Recurrence

The U.S. Food and Drug Administration has granted fast track designation for Greenwich LifeSciences’ lead immunotherapy candidate GLSI-100 in HLA-A*02–positive, HER2-positive breast cancer patients who have completed standard HER2-targeted therapy.

IVIG Reduces Infections Following BsAB Therapies in Multiple Myeloma Patients

A recent study showed treatment with intravenous immune globulin following infection from BCMA therapies yielded a 67 percent decrease in infections in patients with multiple myeloma.

FDA Expands Approval for Recombinant VWF

The U.S. Food and Drug Administration has expanded the approval of recombinant von Willebrand factor, marketed as Vonvendi.